Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation

Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation

Type I Interferonopathies comprise inherited inflammatory diseases associated with perturbation of the type I IFN response. Use of Janus kinase (JAK) inhibitors has been recently reported as possible tools for treating some of those rare diseases. We describe herein the clinical picture and treatmen...

Full description

Bibliographic Details
Main Authors: Marco Cattalini, Jessica Galli, Fiammetta Zunica, Rosalba Monica Ferraro, Marialuisa Carpanelli, Simona Orcesi, Giovanni Palumbo, Lorenzo Pinelli, Silvia Giliani, Elisa Fazzi, Raffaele Badolato
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Pediatrics
Subjects:
interferonopathies
JAK-inhibitor
Aicardi-Goutières syndrome
ruxolitinib
type I interferon
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2021.725868/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2021.725868/full

Similar Items